Press release
Accredited case-based chronic urticaria CME available for free on epgonline.org
A new video-based online CME activity has been added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre on epgonline.org. This activity is intended for allergists, dermatologists and other healthcare professionals involved in the care and treatment of patients with CSU.Chronic urticaria is thought to affect up to 1% of the population at any given time, with two-thirds of the cases thought to be spontaneous or idiopathic1. The lifetime prevalence of this condition is thought to be between 0.6 and 1.8%2,3. CSU can have a profound impact on patients’ quality of life with many aspects reduced or impaired. At least 50% of patients will experience at least one recurrence of symptoms after a resolution.5
The activity ‘Case Consults: Changing Paradigms in the Age of Biologics’ has received accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) and is worth 1 CME credit. Participants must watch three video presentations and two video case studies and complete the accompanying quiz questions. These videos are based on expert-led sessions from a symposium of the same name held at the 24th European Academy of Dermatology and Venereology (EADV) Congress 2015.
To find out more information such as learning objectives, system requirements, faculty biographies and discretions and to complete the activity, please visit the following link: http://www.epgonline.org/csu-knowledge-centre/cme/. In order to complete this activity, participants must be a (free) registered user of epgonline.org. There is no fee for this activity and a certificate is available to download on completion. In addition to the CME, registered users also have unlimited access to the disease awareness information, diagnostic tools, treatment guidelines, symposium highlights, video channel and resources section within the CSU Knowledge Centre.
Dr Toby Galbraith, Director of Content Strategy for epgonline.org, said: “This faculty-led educational module has been developed with an important set of learning objectives in mind. The intention is to aid healthcare professionals in effectively identifying and treating this condition using real life patient cases.” This activity is supported by funding from Novartis Pharma AG.
ENDS
Notes to Editors:
• EPG Health Media (Europe) Ltd publishes www.epgonline.org, an independent website dedicated to providing healthcare professionals worldwide with free access to a comprehensive range of disease and medicines information. Categorised by medical specialty, content within epgonline.org includes a multi-language database of approved medications, treatment guidelines, clinical trial reports, journal abstracts, latest medical industry news, apps and a blog written by members.
• Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.
References:
1. Maurer M et al. Allergy 2011;66:317-330.
2. Gaig P et al. J Investig Allergol Clin Immunol. 2004;14:214-220.
3. Zuberbier T et al. Clin Exp Dermatol 2010;35:869-873.
4. Kang MJ et al. Ann Dermatol 2009;21:226-229.
5. Hellgren L. Acta Allergol 1972;27:236-240.
EPG Health Media (Europe) Ltd publishes www.epgonline.org, an independent website dedicated to providing healthcare professionals worldwide with free access to a comprehensive range of disease and medicines information. Categorised by medical specialty, content within epgonline.org includes a multi-language database of approved medications, treatment guidelines, clinical trial reports, journal abstracts, latest medical industry news, apps and a blog written by members.
EPG Health Media (Europe) Ltd
51-55 The Pantiles
Tunbridge Wells
Kent
TN2 5TE
Kristie Marchant
Marketing Executive
press@epghealthmedia.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Accredited case-based chronic urticaria CME available for free on epgonline.org here
News-ID: 324592 • Views: …
More Releases from EPG Health Media
New clinical resource presents the latest evidence of effective procedures for f …
epgonline.org is pleased to announce the latest addition to its range of educational resources for healthcare professionals. The Fluid Management Knowledge Centre is intended as a learning tool to educate healthcare professionals on effective procedures for fluid management in a selection of clinical scenarios.
Currently, the choice of intravenous fluids used for the resuscitation of acutely ill patients in clinical practice is determined mainly by clinician preference1. However, emerging evidence…
New Breast Cancer Knowledge Centre launches on epgonline.org, the website for he …
A new clinical resource has launched on epgonline.org this week. The Breast Cancer Knowledge Centre is intended for oncologists and other healthcare professionals involved in the treatment and care of patients with this condition.
Breast cancer is the second most common cancer worldwide. It has the highest 5-year global prevalence of any cancer type, which is estimated to have increased by 21% since 2008 to 6.3 million women in 20121.…
New multi-language Transplantation Knowledge Centre for healthcare professionals …
A new clinical resource has launched on epgonline.org, the website for healthcare professionals. The Transplantation Knowledge Centre is intended as a learning tool to provide online access to information on a variety of topics related to transplantation, including surgical procedures and future developments in the field.
Although short term survival of transplantation surgery is excellent (>90%), long term survival rates are poor due to recurrence of disease, development of…
New hidradenitis suppurativa (acne inversa) clinical resource launches this week …
epgonline.org, the website for healthcare professionals, has recently announced the addition of a new clinical resource on hidradenitis suppurativa (HS), also known as acne inversa. The Hidradenitis Suppurativa Knowledge Centre presents information in a series of key sections, including disease awareness information and treatment options using both conventional and newer biologic agents.
HS is a chronic, recurrent, inflammatory skin disease, which commonly develops post-puberty in skin regions bearing apocrine glands,…
More Releases for Novartis
Oncology Drugs Market Competitive Outlook - GlaxoSmithKline, Novartis, Merck
"The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to…
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought…
Gleevec Market Overall Study Report 2020-2027 | Novartis
Gleevec Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Gleevec market between 2020 and 2027. In terms of value, the Gleevec industry is expected to register a steady CAGR during the forecast period.
The report offers a systematic presentation of the existing trends,…
Rydapt Market Demand & Competitive Analysis by 2025| Novartis
Market Research Report Store offers a latest published report on Rydapt Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth…
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports.
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
In 2018, the global HER2-negative breast cancer Treatment…
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis.
Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896
Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are…
